Your browser is no longer supported. Please, upgrade your browser.
FUSN Fusion Pharmaceuticals Inc. monthly Stock Chart
FUSN [NASD]
Fusion Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-17.69 Insider Own9.00% Shs Outstand41.66M Perf Week-2.21%
Market Cap511.75M Forward P/E- EPS next Y-0.17 Insider Trans0.00% Shs Float18.87M Perf Month0.98%
Income-65.10M PEG- EPS next Q-0.14 Inst Own81.80% Short Float1.43% Perf Quarter-4.18%
Sales- P/S- EPS this Y-38.90% Inst Trans0.07% Short Ratio4.61 Perf Half Y-
Book/sh133.21 P/B0.09 EPS next Y85.00% ROA- Target Price- Perf Year-
Cash/sh7.71 P/C1.60 EPS next 5Y- ROE- 52W Range11.50 - 19.00 Perf YTD-27.24%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-34.89% Beta-
Dividend %- Quick Ratio42.10 Sales past 5Y- Gross Margin- 52W Low7.57% ATR0.55
Employees41 Current Ratio42.10 Sales Q/Q- Oper. Margin- RSI (14)49.33 Volatility3.40% 5.01%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.13 Prev Close12.34
ShortableYes LT Debt/Eq0.00 EarningsAug 11 BMO Payout- Avg Volume58.66K Price12.37
Recom1.50 SMA201.45% SMA50-1.20% SMA200-8.55% Volume7,773 Change0.24%
Jul-21-20Initiated Wedbush Outperform $25
Jul-21-20Initiated Jefferies Buy $25
Jul-21-20Initiated Cowen Outperform
Oct-11-20 09:30AM  
Sep-29-20 04:15PM  
04:15PM  
Sep-27-20 10:18AM  
Sep-10-20 09:00AM  
Aug-11-20 07:25AM  
Aug-05-20 08:00AM  
Jul-14-20 09:30AM  
Jul-10-20 05:13PM  
Jun-25-20 10:39PM  
10:39PM  
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.